Phentolamine: Night Driving After Surgery – Phase 3 Results
- A new phentolamine ophthalmic solution 0.75% may offer relief for individuals experiencing chronic night driving impairment following keratorefractive procedures.
- The double-masked LYNX-2 trial involved 199 patients who reported decreased visual acuity in low-light conditions after undergoing keratorefractive surgery.
- Patients also reported statistically significant improvements in night driving, noting reduced difficulty seeing the road due to oncoming headlights and glare at dawn or dusk.
Discover how a new eye drop, phentolamine ophthalmic solution 0.75%, could revolutionize night driving for those with vision impairment after eye surgery. Phase 3 clinical trial results reveal significant improvements in mesopic low contrast distance visual acuity within just 15 days of use of this new primary_keyword . Patients also reported enhanced night driving abilities, indicating a reduction in glare and improved visibility.The study, involving nearly 200 patients, underscores the potential of this secondary_keyword to improve quality of life. News Directory 3 is following the story closely. The eye drop will require a prescription. What’s next for this breakthrough treatment? Discover what’s next ….
Eye Drop Shows Promise for Night Vision Impairment After Eye Surgery
Updated June 06, 2025
A new phentolamine ophthalmic solution 0.75% may offer relief for individuals experiencing chronic night driving
impairment following keratorefractive procedures. According to Opus Genetics,a phase 3 clinical trial demonstrated
significant improvements with this novel eye drop.
The double-masked LYNX-2 trial involved 199 patients who reported decreased visual acuity in low-light conditions
after undergoing keratorefractive surgery. Participants were randomly assigned to receive either phentolamine
ophthalmic solution or a placebo nightly for six weeks. After 15 days, 17.3% of those treated with phentolamine
showed an improvement of at least 15 letters on the ETDRS chart, compared to 9.2% in the placebo group (P <
.05). This highlights the potential of phentolamine ophthalmic solution for improving mesopic low contrast distance
visual acuity.
Patients also reported statistically significant improvements in night driving, noting reduced difficulty seeing the
road due to oncoming headlights and glare at dawn or dusk.
The long-term safety of phentolamine ophthalmic solution will be monitored for 48 weeks.
“LYNX-2 represents an vital step forward in addressing a widespread and often undertreated visual issue that
affects many patients following refractive surgery,” George Magrath, MD, CEO of Opus Genetics, told Healio. “This
product has the potential to improve quality of life for a large population, and we’re excited by its promise.”
magrath added that Opus Genetics is currently determining the best path forward with the FDA for phentolamine
ophthalmic solution. The product will be available by prescription only.
The eye drop functions by reducing pupil size through a sympatholytic mechanism, avoiding engagement of the ciliary
muscle.This may lower the risk of retinal tears or detachment, sometimes associated with older parasympathomimetic
agents.
The FDA previously granted fast track designation to phentolamine ophthalmic solution 0.75% in February.
What’s next
Opus Genetics is in the planning stages of working with the FDA to determine the next steps for phentolamine
ophthalmic solution 0.75%.